# Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

> **NCT06897605** · PHASE2 · RECRUITING · sponsor: **Mansoura University** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Kidney Disease(CKD)
- Anemia, Kidney Disease, Chronic

## Interventions

- **DRUG:** Dapagliflozin (DAPA)
- **DRUG:** Erythropoiesis Stimulating Agent

## Key facts

- **NCT ID:** NCT06897605
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06897605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06897605, "Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06897605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*